B-intervention	0	6	Breast
I-intervention	6	7	-
I-intervention	7	19	conservative
I-intervention	20	27	surgery
I-intervention	28	32	with
I-intervention	33	36	and
I-intervention	37	44	without
I-intervention	45	57	radiotherapy
O	58	60	in
O	61	69	patients
O	70	74	aged
B-age	75	77	55
I-age	77	78	-
I-age	78	80	75
I-age	81	86	years
O	87	91	with
O	92	97	early
O	97	98	-
O	98	103	stage
O	104	110	breast
O	111	117	cancer
O	117	118	:
O	119	120	a
O	121	132	prospective
O	132	133	,
O	134	144	randomized
O	144	145	,
O	146	157	multicenter
O	158	163	trial
O	164	172	analysis
O	173	178	after
O	179	182	108
O	183	189	months
O	190	192	of
O	193	199	median
O	200	206	follow
O	206	207	-
O	207	209	up
O	209	210	.

O	211	217	Breast
O	217	218	-
O	218	228	conserving
O	229	236	therapy
O	237	238	(
O	238	241	BCT
O	241	242	)
O	242	243	,
O	244	253	including
O	254	267	postoperative
O	268	273	whole
O	274	280	breast
O	281	292	irradiation
O	293	294	(
O	294	297	WBI
O	297	298	)
O	298	299	,
O	300	302	is
O	303	312	generally
O	313	321	accepted
O	322	324	as
O	325	328	the
O	329	338	treatment
O	339	341	of
O	342	348	choice
O	349	352	for
O	353	357	most
O	358	366	patients
O	367	371	with
O	372	377	early
O	377	378	-
O	378	383	stage
O	384	390	breast
O	391	397	cancer
O	397	398	.

O	399	402	The
O	403	411	question
O	412	419	whether
O	420	423	WBI
O	424	426	is
O	427	436	mandatory
O	437	439	in
O	440	443	all
O	444	452	patients
O	453	460	remains
O	461	464	one
O	465	467	of
O	468	471	the
O	472	476	most
O	477	490	controversial
O	491	497	issues
O	498	500	in
O	501	504	BCT
O	504	505	.

O	506	508	To
O	509	515	answer
O	516	520	this
O	521	529	question
O	529	530	,
O	531	532	a
O	533	543	randomized
O	543	544	,
O	545	556	prospective
O	556	557	,
O	558	569	multicentre
O	570	575	study
O	576	579	was
O	580	588	launched
O	589	591	in
O	592	599	January
O	600	604	2001
O	604	605	.

O	606	613	Primary
O	614	623	endpoints
O	624	626	of
O	627	630	the
O	631	636	study
O	637	641	were
O	642	644	to
O	645	651	assess
O	652	655	the
B-outcome-Measure	656	666	cumulative
I-outcome-Measure	667	676	incidence
I-outcome-Measure	677	679	of
I-outcome-Measure	680	682	in
I-outcome-Measure	682	683	-
I-outcome-Measure	683	689	breast
I-outcome-Measure	689	690	-
I-outcome-Measure	690	701	recurrences
I-outcome-Measure	702	703	(
I-outcome-Measure	703	706	IBR
I-outcome-Measure	706	707	)
O	708	711	and
B-outcome-Measure	712	719	overall
I-outcome-Measure	720	728	survival
I-outcome-Measure	729	730	(
I-outcome-Measure	730	733	OAS
I-outcome-Measure	733	734	)
O	735	740	after
O	741	753	conservative
O	754	761	surgery
O	762	763	(
O	763	766	BCS
O	766	767	)
O	768	772	with
O	773	775	or
O	776	783	without
O	784	787	WBI
O	787	788	.

O	789	793	From
O	794	801	January
O	802	806	2001
O	807	812	until
O	813	821	December
O	822	826	2005
O	826	827	,
B-total-participants	828	831	749
B-eligibility	832	840	patients
I-eligibility	841	845	with
I-eligibility	846	854	unifocal
I-eligibility	855	867	infiltrating
I-eligibility	868	874	breast
I-eligibility	875	881	cancer
I-eligibility	882	884	up
I-eligibility	885	887	to
I-eligibility	888	890	25
I-eligibility	891	893	mm
I-eligibility	893	894	,
I-eligibility	895	896	0
I-eligibility	896	897	-
I-eligibility	897	898	3
I-eligibility	899	907	positive
I-eligibility	908	916	axillary
I-eligibility	917	922	lymph
I-eligibility	923	928	nodes
I-eligibility	928	929	,
I-eligibility	930	932	no
I-eligibility	933	942	extensive
I-eligibility	943	954	intraductal
I-eligibility	955	964	component
I-eligibility	965	967	or
I-eligibility	968	981	lymphvascular
I-eligibility	982	990	invasion
O	991	995	from
O	996	998	11
O	999	1006	centres
O	1007	1009	in
B-location	1010	1015	Italy
O	1015	1016	,
O	1017	1021	were
O	1022	1030	randomly
O	1031	1039	assigned
O	1040	1042	to
O	1043	1046	BCS
O	1046	1047	+
O	1047	1050	WBI
O	1051	1052	(
O	1052	1055	arm
O	1056	1057	1
O	1057	1058	:
B-intervention-participants	1058	1061	373
O	1062	1070	patients
O	1070	1071	)
O	1072	1074	or
B-control	1075	1078	BCS
I-control	1079	1084	alone
O	1085	1086	(
O	1086	1089	arm
O	1090	1091	2
O	1091	1092	:
B-control-participants	1092	1095	376
O	1096	1104	patients
O	1104	1105	)
O	1105	1106	.

O	1107	1116	Treatment
O	1117	1121	arms
O	1122	1126	were
O	1127	1131	well
O	1132	1140	balanced
O	1141	1143	in
O	1144	1149	terms
O	1150	1152	of
O	1153	1161	baseline
O	1162	1177	characteristics
O	1177	1178	.

O	1179	1187	Systemic
O	1188	1196	adjuvant
O	1197	1204	therapy
O	1205	1208	was
O	1209	1221	administered
O	1222	1231	according
O	1232	1234	to
O	1235	1238	the
O	1239	1252	institutional
O	1253	1261	policies
O	1261	1262	.

O	1263	1269	Kaplan
O	1269	1270	-
O	1270	1275	Meier
O	1276	1282	method
O	1283	1286	was
O	1287	1291	used
O	1292	1295	for
O	1296	1304	survival
O	1305	1313	analysis
O	1314	1317	and
O	1318	1321	log
O	1321	1322	-
O	1322	1326	rank
O	1327	1331	test
O	1332	1334	to
O	1335	1343	evaluate
O	1344	1347	the
O	1348	1358	difference
O	1359	1366	between
O	1367	1370	the
O	1371	1374	two
O	1375	1379	arms
O	1379	1380	.

O	1381	1388	RESULTS
O	1389	1390	(
O	1390	1394	Last
O	1395	1403	analysis
O	1404	1406	31
O	1406	1407	.
O	1407	1409	12
O	1409	1410	.
O	1410	1414	2012
O	1414	1415	)
O	1415	1416	:
O	1417	1422	After
O	1423	1429	median
O	1430	1436	follow
O	1436	1437	-
O	1437	1439	up
O	1440	1442	of
O	1443	1446	108
O	1447	1453	months
O	1453	1454	,
B-iv-bin-abs	1455	1457	12
O	1458	1459	(
B-iv-bin-percent	1459	1460	3
I-iv-bin-percent	1460	1461	.
I-iv-bin-percent	1461	1462	4
I-iv-bin-percent	1462	1463	%
O	1463	1464	)
B-outcome	1465	1468	IBR
O	1469	1473	were
O	1474	1482	observed
O	1483	1485	in
O	1486	1489	arm
O	1490	1491	1
O	1492	1495	and
B-cv-bin-abs	1496	1498	16
O	1499	1500	(
B-cv-bin-percent	1500	1501	4
I-cv-bin-percent	1501	1502	.
I-cv-bin-percent	1502	1503	4
I-cv-bin-percent	1503	1504	%
O	1504	1505	)
O	1506	1508	in
O	1509	1512	arm
O	1513	1514	2
O	1514	1515	.

B-outcome	1516	1519	OAS
O	1520	1523	was
B-iv-bin-percent	1524	1526	81
I-iv-bin-percent	1526	1527	.
I-iv-bin-percent	1527	1528	4
I-iv-bin-percent	1528	1529	%
O	1530	1532	in
O	1533	1536	arm
O	1537	1538	1
O	1539	1542	and
B-cv-bin-percent	1543	1545	83
I-cv-bin-percent	1545	1546	.
I-cv-bin-percent	1546	1547	7
I-cv-bin-percent	1547	1548	%
O	1549	1551	in
O	1552	1555	arm
O	1556	1557	2
O	1557	1558	.

O	1559	1564	There
O	1565	1568	was
O	1569	1571	no
O	1572	1585	statistically
O	1586	1597	significant
O	1598	1608	difference
O	1609	1618	regarding
B-outcome	1619	1622	IBR
I-outcome	1623	1626	and
I-outcome	1627	1632	death
O	1633	1635	in
O	1636	1639	the
O	1640	1643	two
O	1644	1653	treatment
O	1654	1660	groups
O	1660	1661	.

O	1662	1667	These
O	1668	1672	data
O	1673	1676	are
O	1677	1686	promising
O	1687	1690	and
O	1691	1698	suggest
O	1699	1703	that
O	1704	1707	WBI
O	1708	1713	after
O	1714	1717	BCS
O	1718	1721	can
O	1722	1724	be
O	1725	1732	omitted
O	1733	1735	in
O	1736	1744	selected
O	1745	1753	patients
O	1754	1758	with
O	1759	1764	early
O	1765	1770	stage
O	1771	1777	breast
O	1778	1784	cancer
O	1785	1792	without
O	1793	1801	exposing
O	1802	1806	them
O	1807	1809	to
O	1810	1812	an
O	1813	1822	increased
O	1823	1827	risk
O	1828	1830	of
O	1831	1836	local
O	1837	1847	recurrence
O	1848	1851	and
O	1852	1857	death
O	1857	1858	.

O	1859	1865	Longer
O	1866	1872	follow
O	1872	1873	-
O	1873	1875	up
O	1876	1878	is
O	1879	1885	needed
O	1886	1888	to
O	1889	1896	further
O	1897	1908	consolidate
O	1909	1914	these
O	1915	1922	results
O	1922	1923	.
